Laxxon Medical to Make 3D Printed Pills

17 March 2022: Evonik Venture Capital has invested in the Nevada-based Laxxon Medical to produce 3D-printed tablets that will improve patient health thanks to better drug delivery. Evonik, with decades of experience in the field of active medical ingredients, has developed a 3D screen-printing technology that makes it possible to produce structured tablets which can control the release of active pharmaceutical ingredients over time.

Using their new 3D screen printing technology, tablets can be easily produced with different active and inactive layers. Thanks to Laxxon’s technology, the printing speed is significantly faster than already proven 3D printing processes, which could even enable mass production. Pharmaceutical companies could also soon expand their existing patents through improved drug delivery. This indicates that a shortage of drugs may soon be a thing of the past.

Laxxon was founded in 2017 by Helmut Kerschbaumer, Klaus Kühne and Achim Schneeberger in Switzerland, but the company is now headquartered in the USA and has a German and Swiss subsidiary.